Neurological Disease as a Failure of Brain–Immune Crosstalk: The Multiple Faces of Neuroinflammation

Trends in Immunology

Volumn 37, Issue 10, 2016, Pages 668-679

  Schwartz, Michal ^a   Deczkowska, Aleksandra ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Alzheimer's disease; choroid plexus; CNS immune surveillance; interferon; multiple sclerosis; neurodegenerative disease

Indexed keywords

BIODIVERSITY; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; HEALTH STATUS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; NERVOUS SYSTEM INFLAMMATION; NEUROIMMUNOLOGY; NEUROLOGIC DISEASE; NONHUMAN; PHENOTYPIC VARIATION; REVIEW; ALZHEIMER DISEASE; ANIMAL; BRAIN; DISEASE MODEL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MOUSE; MULTIPLE SCLEROSIS; NEUROGENIC INFLAMMATION;

INTERFERON;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNE SYSTEM; INTERFERONS; MICE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROGENIC INFLAMMATION; NEUROIMMUNOMODULATION;

EID: 84994875763     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.08.001     Document Type: Review

References (116)

1. 1 Buckley, C.D., et al. The resolution of inflammation. Nat. Rev. Immunol. 13 (2013), 59–66.
2. 2 Lynch, M.A., Age-related neuroinflammatory changes negatively impact on neuronal function. Front. Aging Neurosci., 1, 2010, 6.
3. 3 Heppner, F.L., et al. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16 (2015), 358–372.
4. 4 Heneka, M.T., O'Banion, M.K., Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 184 (2007), 69–91.
5. 5 Frank-Cannon, T.C., et al. Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol. Neurodegen. 4 (2009), 1–13.
6. 6 Dendrou, C.A., et al. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15 (2015), 545–558.
7. 7 Schwartz, M., Shechter, R., Systemic inflammatory cells fight off neurodegenerative disease. Nat. Rev. Neurol. 6 (2010), 405–410.
8. 8 Rapalino, O., et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med. 4 (1998), 814–821.
9. 9 Moalem, G., et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5 (1999), 49–55.
10. 10 Yoles, E., et al. Protective autoimmunity is a physiological response to CNS trauma. J. Neurosci. 21 (2001), 3740–3748.
11. 11 Galea, I., et al. What is immune privilege (not)?. Trends Immunol. 28 (2007), 12–18.
12. 12 Louveau, A., et al. Revisiting the mechanisms of CNS immune privilege. Trends Immunol. 36 (2015), 569–577.
13. 13 Schwartz, M., Shechter, R., Protective autoimmunity functions by intracranial immunosurveillance to support the mind: the missing link between health and disease. Mol. Psychiatry 15 (2010), 342–354.
14. 14 Kipnis, J., et al. Pro-cognitive properties of T cells. Nat. Rev. Immunol. 12 (2012), 663–669.
15. 15 Schwartz, M., Baruch, K., The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J. 33 (2014), 7–22.
16. 16 Fletcher, J.M., et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162 (2010), 1–11.
17. 17 Viglietta, V., et al. Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199 (2004), 971–979.
18. 18 Joller, N., et al. Immune checkpoints in central nervous system autoimmunity. Immunol. Rev. 248 (2012), 122–139.
19. 19 Prinz, M., Priller, J., Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat. Rev. Neurosci. 15 (2014), 300–312.
20. 20 Pierrot-Deseilligny, C., Souberbielle, J.C., Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Ther. Adv. Neurol. Disord. 6 (2013), 81–116.
21. 21 Spinas, E., et al. Crosstalk between vitamin B and immunity. J. Biol. Regul. Homeost. Agents 29 (2015), 283–288.
22. 22 Huang, H-C., Jiang, Z-F., Accumulated amyloid-β peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J. Alzheimers Dis. 16 (2009), 15–27.
23. 23 Zenaro, E., et al. Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin. Nat. Med. 21 (2015), 880–886.
24. 24 Hohsfield, L.A., Humpel, C., Migration of blood cells to β-amyloid plaques in Alzheimer's disease. Exp. Gerontol. 65 (2015), 8–15.
25. 25 Baruch, K., et al. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology. Nat. Commun., 6, 2015, 7967.
26. 26 Baruch, K., et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. Nat. Med. 22 (2016), 135–137.
27. 27 Ginhoux, F., et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330 (2010), 841–845.
28. 28 Matcovitch-Natan, O., et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science, 2016, 23.
29. 29 Crotti, A., Ransohoff, R.M., Microglial physiology and pathophysiology: insights from genome-wide transcriptional profiling. Immunity 44 (2016), 505–515.
30. 30 Butovsky, O., et al. Identification of a unique TGF-[beta]-dependent molecular and functional signature in microglia. Nat. Neurosci. 17 (2014), 131–143.
31. 31 Yang, X.W., et al. Safflower yellow regulates microglial polarization and inhibits inflammatory response in LPS-stimulated Bv2 cells. Int. J. Immunopathol. Pharmacol. 29 (2016), 54–64.
32. 32 Gu, Y., et al. Role of TNF in mast cell neuroinflammation and pain. 2015, BIOLIFE SAS VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY.
33. 33 Murphy, Á.C., et al. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav. Immun. 24 (2010), 641–651.
34. 34 Fu, R., et al. Phagocytosis of microglia in the central nervous system diseases. Mol. Neurobiol. 49 (2014), 1422–1434.
35. 35 Lourbopoulos, A., et al. Microglia in action: how aging and injury can change the brain's guardians. Front. Cell. Neurosci., 9, 2015, 54.
36. 36 Goldmann, T., et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat. Neurosci. 16 (2013), 1618–1626.
37. 37 Yamasaki, R., et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 211 (2014), 1533–1549.
38. 38 Prinz, M., et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28 (2008), 675–686.
39. 39 Shechter, R., et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med., 6, 2009, e1000113.
40. 40 Lai, A.Y., McLaurin, J., Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where. Future Neurol. 7 (2012), 165–176.
41. 41 Vainchtein, I.D., et al. In acute experimental autoimmune encephalomyelitis, infiltrating macrophages are immune activated, whereas microglia remain immune suppressed. Glia 62 (2014), 1724–1735.
42. 42 Arellano, G., et al. Stage-specific role of interferon-gamma in experimental autoimmune encephalomyelitis and multiple sclerosis. Front. Immunol., 6, 2015, 492.
43. 43 Cohen, M., et al. Chronic exposure to TGFβ1 regulates myeloid cell inflammatory response in an IRF7 - dependent manner. EMBO J. 33 (2014), 2906–2921.
44. 44 Jay, T.R., et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J. Exp. Med. 212 (2015), 287–295.
45. 45 Wang, Y., et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160 (2015), 1061–1071.
46. 46 Colonna, M., Wang, Y., TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat. Rev. Neurosci. 17 (2016), 201–207.
47. 47 Mildner, A., et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J. Neurosci. 31 (2011), 11159–11171.
48. 48 Yuan, P., et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90 (2016), 724–739.
49. 49 Wang, Y., et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213 (2016), 667–675.
50. 50 Naert, G., Rivest, S., A deficiency in CCR2+ monocytes: the hidden side of Alzheimer's disease. J. Mol. Cell Biol. 5 (2013), 284–293.
51. 51 Town, T., et al. Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 14 (2008), 681–687.
52. 52 Hawkes, C.A., McLaurin, J., Selective targeting of perivascular macrophages for clearance of β-amyloid in cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. 106 (2009), 1261–1266.
53. 53 El Khoury, J., et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13 (2007), 432–438.
54. 54 Koronyo, Y., et al. Therapeutic effects of glatiramer acetate and grafted CD115(+) monocytes in a mouse model of Alzheimer's disease. Brain 138:Pt 8 (2015), 2399–2422.
55. 55 Koronyo-Hamaoui, M., et al. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J. Neurochem. 111 (2009), 1409–1424.
56. 56 Simard, A.R., et al. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49 (2006), 489–502.
57. 57 Zhan, Y., et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat. Neurosci. 17 (2014), 400–406.
58. 58 Costello, D.A., et al. Long term potentiation is impaired in membrane glycoprotein CD200-deficient mice a role for toll-like receptor activation. J. Biol. Chem. 286 (2011), 34722–34732.
59. 59 Chakrabarty, P., et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85 (2015), 519–533.
60. 60 Guillot-Sestier, M-V., et al. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85 (2015), 534–548.
61. 61 London, A., et al. Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages. J. Exp. Med. 208 (2011), 23–39.
62. 62 Raposo, C., et al. CNS repair requires both effector and regulatory T cells with distinct temporal and spatial profiles. J. Neurosci. 34 (2014), 10141–10155.
63. 63 Endo, F., et al. Astrocyte-derived TGF-β1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 11 (2015), 592–604.
64. 64 Kunis, G., et al. Immunization with a myelin-derived antigen activates the brain's choroid plexus for recruitment of immunoregulatory cells to the CNS and attenuates disease progression in a mouse model of ALS. J. Neurosci. 35 (2015), 6381–6393.
65. 65 Lassmann, H., et al. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 8 (2012), 647–656.
66. 66 Matzinger, P., Kamala, T., Tissue-based class control: the other side of tolerance. Nat. Rev. Immunol. 11 (2011), 221–230.
67. 67 Kunis, G., et al. IFN-gamma-dependent activation of the brain's choroid plexus for CNS immune surveillance and repair. Brain 136:Pt 11 (2013), 3427–3440.
68. 68 Baruch, K., et al. Cerebral nitric oxide represses choroid plexus NFκB - dependent gateway activity for leukocyte trafficking. EMBO J., 2015, e201591468.
69. 69 Shechter, R., et al. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat. Rev. Immunol. 13 (2013), 206–218.
70. 70 Goldmann, T., et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol. 17 (2016), 797–805.
71. 71 Derecki, N.C., et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J. Exp. Med. 207 (2010), 1067–1080.
72. 72 Radjavi, A., et al. Dynamics of the meningeal CD4(+) T-cell repertoire are defined by the cervical lymph nodes and facilitate cognitive task performance in mice. Mol. Psychiatry 19 (2014), 531–533.
73. 73 Radjavi, A., et al. Brain antigen-reactive CD4+ T cells are sufficient to support learning behavior in mice with limited T cell repertoire. Brain Behav. Immun. 35 (2014), 58–63.
74. 74 Marques, F., et al. Kinetic profile of the transcriptome changes induced in the choroid plexus by peripheral inflammation. J. Cereb. Blood Flow Metab. 29 (2009), 921–932.
75. 75 Marques, F., et al. The choroid plexus response to a repeated peripheral inflammatory stimulus. BMC Neurosci., 10, 2009, 135.
76. 76 Falcao, A.M., et al. The path from the choroid plexus to the subventricular zone: go with the flow!. Front. Cell. Neurosci., 6, 2012, 34.
77. 77 Emerich, D.F., et al. The choroid plexus in the rise, fall and repair of the brain. Bioessays 27 (2005), 262–274.
78. 78 Johanson, C.E., et al. The blood-cerebrospinal fluid barrier: structure and functional significance. Methods Mol. Biol. 686 (2011), 101–131.
79. 79 Meeker, R.B., et al. Cell trafficking through the choroid plexus. Cell Adh. Migr. 6 (2012), 390–396.
80. 80 Steffen, B.J., et al. ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro. Am. J. Pathol., 148, 1996, 1819.
81. 81 Deczkowska, A., et al. Type I/II interferon balance in the regulation of brain physiology and pathology. Trends Immunol. 37 (2016), 181–192.
82. 82 Baruch, K., et al. CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 2264–2269.
83. 83 Purwar, R., et al. Resident memory T cells (T RM) are abundant in human lung: diversity, function, and antigen specificity. PloS ONE, 6, 2011, e16245.
84. 84 Reboldi, A., et al. CC chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10 (2009), 514–523.
85. 85 Mesquita, S.D., et al. The choroid plexus transcriptome reveals changes in type I and II interferon responses in a mouse model of Alzheimer's disease. Brain Behav. Immun. 49 (2015), 280–292.
86. 86 Garg, S.K., et al. Aging is associated with increased regulatory T - cell function. Aging Cell 13 (2014), 441–448.
87. 87 Shearer, G.M., Th1/Th2 changes in aging. Mech. Ageing Dev. 94 (1997), 1–5.
88. 88 Baruch, K., et al. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346 (2014), 89–93.
89. 89 Butovsky, O., et al. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur. J. Neurosci. 26 (2007), 413–416.
90. 90 Farrall, A.J., Wardlaw, J.M., Blood–brain barrier: ageing and microvascular disease–systematic review and meta-analysis. Neurobiol. Aging 30 (2009), 337–352.
91. 91 Shechter, R., et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 38 (2013), 555–569.
92. 92 Ma, M., et al. Monocyte recruitment and myelin removal are delayed following spinal cord injury in mice with CCR2 chemokine receptor deletion. J. Neurosci. Res. 68 (2002), 691–702.
93. 93 McTigue, D.M., et al. Selective chemokine mRNA accumulation in the rat spinal cord after contusion injury. J. Neurosci. Res. 53 (1998), 368–376.
94. 94 Mohammad, M.G., et al. Immune cell trafficking from the brain maintains CNS immune tolerance. J. Clin. Invest. 124 (2014), 1228–1241.
95. 95 Aspelund, A., et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212 (2015), 991–999.
96. 96 Louveau, A., et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523 (2015), 337–341.
97. 97 Ellwardt, E., et al. Understanding the role of T cells in CNS homeostasis. Trends Immunol. 37 (2016), 154–165.
98. 98 Weller, R.O., et al. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol. 117 (2009), 1–14.
99. 99 Laman, J.D., Weller, R.O., Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J. Neuroimmune Pharmacol. 8 (2013), 840–856.
100. 100 Ransohoff, R.M., et al. Multiple sclerosis — a quiet revolution. Nat. Rev. Neurol. 11 (2015), 134–142.
101. 101 Baroncini, D., et al. A real world experience with fingolimod in active RRMS patients naïve to second-line agents: a 2 years, intention-to-treat, observational, single center study. Multiple Sclerosis and Demyelinating Disorders, 1, 2016, 1.
102. 102 Schenk, D., et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999), 173–177.
103. 103 Janus, C., et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000), 979–982.
104. 104 Weber, M.S., et al. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 4 (2007), 647–653.
105. 105 Arnon, R., Sela, M., Immunomodulation by the copolymer glatiramer acetate. J. Mol. Recogn. 16 (2003), 412–421.
106. 106 Meininger, V., et al. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler. 10 (2009), 378–383.
107. 107 Schwab, N., et al. Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis. Int. Immunol. 27 (2015), 47–53.
108. 108 Yednock, T.A., et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356 (1992), 63–66.
109. 109 Humphries, C., Progressive multiple sclerosis: The treatment gap. Nature, 484, 2012 S10-S10.
110. 110 Stromnes, I.M., et al. Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells. Nat. Med. 14 (2008), 337–342.
111. 111 Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
112. 112 Wenk, G.L., Neuropathologic changes in Alzheimer's disease: potential targets for treatment. J. Clin. Psychiatry 67:Suppl. 3 (2006), 3–7 quiz 23.
113. 113 Hickman, S.E., et al. Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28 (2008), 8354–8360.
114. 114 Fabis, M.J., et al. Loss of blood–brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 5656–5661.
115. 115 Engelhardt, B., et al. Involvement of the choroid plexus in central nervous system inflammation. Microsc. Res. Tech. 52 (2001), 112–129.
116. 116 Ontaneda, D., Rae-Grant, A.D., Management of acute exacerbations in multiple sclerosis. Ann. Indian Acad. Neurol. 12 (2009), 264–272.